source
- AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart diseaseResults published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
- Teva named stalking horse bidder to acquire BioXcel's neuroscience assets for $57.5 millionBioXcel Therapeutics, a Connecticut biotech focused on neuroscience, filed for Chapter 11 bankruptcy after running out of cash to fund operations through August. In the filing, the company selecte…